Paul Alabanza
About
In The Last Decade
Paul Alabanza
4 papers receiving 234 citations
Hit Papers
Peers
Comparison fields: 5 of 51
- Infectious Diseases 210
- Epidemiology 64
- Neurology 40
- Molecular Biology 29
- Computational Theory and Mathematics 23
Countries citing papers authored by Paul Alabanza
This map shows the geographic impact of Paul Alabanza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Alabanza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Alabanza more than expected).
Fields of papers citing papers by Paul Alabanza
This network shows the impact of papers produced by Paul Alabanza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Alabanza. The network helps show where Paul Alabanza may publish in the future.
Co-authorship network of co-authors of Paul Alabanza
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Alabanza. A scholar is included among the top collaborators of Paul Alabanza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Alabanza. Paul Alabanza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus breakdown → | 230 |
| 3 | Reduction in infectious sars-cov-2 in treatment study of covid-19 with molnupiravir | 9 |
| 4 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.